Praed Pharmaceuticals is biopharmaceutical company founded by industry experts. Our mission is to deliver a next generation treatment for Crohn’s disease. We are developing a promising oral compound, cadazolid, for the treatment of Crohn’s disease.
Products, services, technology
Cadazolid is being developed for Crohn’s disease, a host-microbe inflammatory disorder driven by dysbiosis and pathobionts. Cadazolid is GI-confined, microbiome-sparing, and active against the relevant pathobions such as MAP, Enterococcus and C. difficile. Cadazolid comes with Phase I–III data set.
Cooperation possibilities
Investing or Partnering: We are planning, initiating, and conducting a Phase 2a clinical study, for which we are currently looking for funds as investments or partnering.
- https://praedpharm.com
- +41 79 663 20 68
- Send an email
- Etienne Bucher
